ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Coltman, Leb Lead ASCO, AACR; Young, Busch Presidents Elect; Renalda Hilkemeyer Honored

June 3, 1988

Funding opportunities listed.

March 12, 2004

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

March 29, 2013

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

June 28, 2013

In Brief: Congressmen Press Or More Exploratory Grant Money: Murphy Reelected By UICC

August 6, 1976

FDA’s New Guideline Proposal Meets More NCI Objections

March 19, 1976